Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer

British Journal of Cancer

Volumn 101, Issue 9, 2009, Pages 1529-1536

  Hirata, T ^a   Shimizu, C ^a   Yonemori, K ^a   Hirakawa, A ^b   Kouno, T ^a   Tamura, K ^a   Ando, M ^a   Katsumata, N ^a   Fujiwara, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Breast cancer; Endocrine therapy; Hormone receptor status change; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70350675250     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605360     Document Type: Article

References (15)

1. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC (2008) The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma. Breast J 14: 141-146
2. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168
3. Arens N, Bleyl U, Hildenbrand R (2005) HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 446: 489-496
4. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P, Dogliotti L (1996) Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110
5. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155
6. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628
7. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H (2008) Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy. Breast 17: 523-527
8. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608
9. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B (2003) The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 186: 348-350
10. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: meta-analysis. J Natl Cancer Inst 97: 188-194
11. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, Fehm T (2008) Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 28: 1797-1804
12. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM (2005) HER-2/neu expression in locally advanced breast carcinomas: Pre-and post-neoadjuvant chemotherapy. Breast Cancer 12: 294-298
13. Shet T, Agrawal A, Chinoy R, Havaldar R, Parmar V, Badwe R (2007) Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy-implications for a pathologist. Breast J 13: 457-464
14. Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H, Chollet P (2007) Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12: 636-643
15. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M, Jakesz R (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10: 91-98